Glossary
340B drug pricing program
A federal program that makes drug makers sell outpatient drugs at discounts to safety-net hospitals and clinics, which can then bill payers at higher rates.
Also called: 340B, 340B Drug Pricing Program, 340B discount program
The 340B program, created by Section 340B of the Public Health Service Act in 1992 and run by the Health Resources and Services Administration, requires drug makers that participate in Medicaid to sell outpatient drugs at discounted ceiling prices to eligible "covered entities." These include certain hospitals, federally qualified health center clinics, and other safety-net providers such as Ryan White HIV clinics.
The entity buys at the discount but can bill patients' insurers the usual rate and keep the difference to fund services. As a labeled hypothetical, say a clinic buys a drug for $60 and an insurer pays $100: the $40 margin helps pay for care. The discount goes to the entity, not automatically to you.
Supporters say this stretches scarce resources, including for rural hospitals. Critics say the savings are not always passed to patients, and that growth in contract pharmacy arrangements has strayed from the intent. For Medicare, CMS's calendar year 2027 hospital outpatient final rule, issued November 4, 2026, pays 340B-acquired drugs at average sales price minus 28%, and CMS estimated it would lower patient cost sharing on those drugs.
The common mistake is thinking you can use the program yourself. Eligibility belongs to the provider, so ask whether it is a 340B entity and whether it offers a sliding-scale price. See also medicare drug price negotiation, a separate program.
Last reviewed November 16, 2026